NephroPlus Sets December 10 Launch for IPO to Fund Major Expansion
Asia’s Largest Dialysis Network NephroPlus Unveils ₹353-Crore Fresh Issue in Upcoming IPO
NephroPlus IPO Opens December 10; Global Dialysis Leader Targets Growth and Debt Reduction
Bilkul Bazaar
Ahmedabad | 06 Dec 2025
NephroPlus, Asia’s largest dialysis services provider and the world’s fifth largest by treatments performed in FY25, is set to launch its Initial Public Offering (IPO) on December 10, 2025, closing on December 12, 2025.
The Hyderabad-headquartered company has fixed the price band at ₹438–₹460 per equity share, with a ₹41 discount for eligible employees.
The IPO comprises a fresh issue of equity shares aggregating up to ₹353.4 crore and an Offer for Sale (OFS) of up to 1,12,53,102 equity shares by existing shareholders.
Use of Proceeds
NephroPlus plans to deploy the net proceeds from the fresh issue as follows:
₹129.1 crore for capital expenditure to open new dialysis clinics across India.
₹136 crore for the pre-payment or scheduled repayment of borrowings.
Asia’s Largest Dialysis Network with Global Footprint
Founded in 2009, NephroPlus operates the largest organized dialysis service network in India, with clinics spread across 288 cities in 21 states and four union territories.
Globally, the company runs 519 clinics, including centers in Nepal, the Philippines, and Uzbekistan — where its 165-bed dialysis clinic in Tashkent is currently the largest dialysis clinic in the world.
NephroPlus offers a wide spectrum of renal care services, including haemodialysis, home haemodialysis, hemodiafiltration, holiday dialysis, dialysis on-call, and dialysis on wheels, aiming to provide flexible and patient-friendly treatment options.
The Indian dialysis services market, valued at USD 818 million in FY24, is projected to grow to USD 1,979 million by 2029.
At the Ahmedabad IPO press meet held on Friday, key leadership including Group CEO Rohit Singh, CFO Prashant Goenka, and Poojan Doshi of IIFL Capital addressed the media.
Rohit Singh, Group CEO, NephroPlus, said, “Our mission has always been to ensure that every dialysis patient — whether in a metro or a remote town — receives high-quality, safe, and compassionate care. This IPO is a milestone that will fuel our next phase of expansion as we bring world-class renal therapy closer to millions of Indians.”
Prashant Goenka, CFO, NephroPlus, added, “The fresh issue will strengthen our balance sheet and support strategic growth, including the opening of new clinics and reduction of debt. With a scalable model, advanced technology, and a specialised clinical team, NephroPlus is well-positioned to capture the robust growth of India’s dialysis market.”
📌 NephroPlus IPO Snapshot
Particulars Details
IPO Dates December 10–12, 2025
Price Band ₹438 to ₹460 per share
Employee Discount ₹41 per share
Fresh Issue Size ₹353.4 crore
Offer for Sale 1,12,53,102 equity shares
Use of Funds ₹129.1 cr for new clinics; ₹136 cr for debt repayment
Global Clinics 519 (India, Nepal, Philippines, Uzbekistan)
Largest Clinic 165-bed Tashkent centre — world’s largest dialysis clinic
Founded 2009
Key Services Haemodialysis, home dialysis, HDF, dialysis on call & wheels
Disclaimer: This news is for informational purposes only. Please refer to official offer documents and consult a financial advisor before investing.
Kindly Like the shared links and Subscribe our channel for such valuable updates. https://youtube.com/shorts/jDbW15jkuGk?feature=share https://youtube.com/shorts/ER3nVbpibYQ?feature=share https://youtu.be/NQcSnZGNAFw